Current Size: 100%

Molecular imaging and molecular diagnostics: two sides of the same coin?

Today we are rapidly entering the age of personalized medicine, which means that molecular diagnostic techniques are increasingly used for the guidance of individualized therapy and the prediction of treatment response. As a consequence, the clinical field of pathology is today increasingly converting into a field of molecular pathology strategy. Driven by the recent evolution of technologies, including mass spectrometry and different “-omics” approaches, conventional pathology techniques such as immunohistochemistry are at present frequently accompanied by genetic, epigenetic and proteomic analyses which are available on-site in oncology centres and have become ever cheaper. These technologies enable the identification of diagnostically and therapeutically relevant molecular targets and thus can be directly linked to modern biological treatments . A review of the current literature verifies this concept in early clinical trials, in which a biomarker-driven rationale has been demonstrated to be superior to the conventional “one treatment fits all” concept.

This review was published by Lukas Kenner and co-workers in Eur J Nucl Med Mol Imaging. 2018 Jun 2. doi: 10.1007/s00259-018-4060-x